Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
The HLA region in multiple sclerosis.
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy.
The role of mast cells in neuroinflammation.
Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
Fingolimod (Gilenya) eligibility extended by NHS England
Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression.
Remission with fingolimod in a case of demyelinating polyneuropathy.
The Treatment experience, burden, and unmet needs (TRIBUNE) study - measuring the socioeconomic consequences of Multiple Sclerosis.
Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
Purification of Mouse Brain Vessels.
Notable Increased Cerebrospinal Fluid Levels of Soluble Interleukin-6 Receptors in Neuromyelitis Optica.
Mast cells and inflammation.
Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.
Clinical predictors of an optimal response to natalizumab in multiple sclerosis.
New hope for multiple sclerosis patients.
Method for the systematic reviews on occupational therapy and neurodegenerative diseases.
Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies.
18F-FDG PET/CT in Tumefactive Multiple Sclerosis.
Chiasmal optic neuritis in a 4-year-old girl: a case report and review of the literature.
Cerebral white matter blood flow and energy metabolism in multiple sclerosis.
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis.
Autophagy and autoimmunity crosstalks.
Protocol to isolate a large amount of functional oligodendrocyte precursor cells from the cerebral cortex of adult mice and humans.
Improving the clinical correlation of multiple sclerosis black hole volume change by paired-scan analysis.
Cervical dysplasia associated with the use of natalizumab.
Pages
« first
‹ previous
…
249
250
251
252
253
254
255
256
257
…
next ›
last »